CN109662961A - 用于改善认知功能的方法和组合物 - Google Patents

用于改善认知功能的方法和组合物 Download PDF

Info

Publication number
CN109662961A
CN109662961A CN201811403097.5A CN201811403097A CN109662961A CN 109662961 A CN109662961 A CN 109662961A CN 201811403097 A CN201811403097 A CN 201811403097A CN 109662961 A CN109662961 A CN 109662961A
Authority
CN
China
Prior art keywords
base
group
oxo
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811403097.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·加拉格尔
R·哈伯曼
M·T·寇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN109662961A publication Critical patent/CN109662961A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201811403097.5A 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物 Pending CN109662961A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441251P 2011-02-09 2011-02-09
US61/441,251 2011-02-09
CN201280014797XA CN103476255A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280014797XA Division CN103476255A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物

Publications (1)

Publication Number Publication Date
CN109662961A true CN109662961A (zh) 2019-04-23

Family

ID=46638963

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811403097.5A Pending CN109662961A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物
CN201280014797XA Pending CN103476255A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280014797XA Pending CN103476255A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物

Country Status (9)

Country Link
US (2) US20120214859A1 (enExample)
EP (2) EP2672822A4 (enExample)
JP (7) JP2014505108A (enExample)
CN (2) CN109662961A (enExample)
AU (6) AU2012214303A1 (enExample)
BR (1) BR112013020283A2 (enExample)
CA (1) CA2826765C (enExample)
RU (1) RU2665021C2 (enExample)
WO (1) WO2012109491A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115517682A (zh) * 2022-11-25 2022-12-27 四川大学华西医院 基于胃肠电信号的认知功能障碍预测系统及构建方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2018208662B2 (en) * 2012-11-14 2020-07-23 The Johns Hopkins University Methods and Compositions for Treating Schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
WO2014144546A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositons for improving cognitive function
EP2968237A4 (en) * 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
US10159648B2 (en) * 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US20220354807A1 (en) * 2019-09-30 2022-11-10 Xiamen University Use of valeric acid derivative in treatment of down's syndrome
US20250213727A1 (en) 2022-03-25 2025-07-03 Regenxbio Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044878A1 (en) * 2008-10-16 2010-04-22 The Johns Hopkins University Methods and compositions for improving cognitive function
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
CN101027047A (zh) * 2002-12-03 2007-08-29 Ucb公司 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法
JP2006516390A (ja) * 2002-12-03 2006-07-06 ユ セ ベ ソシエテ アノニム 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法
DK1626721T3 (en) * 2003-05-23 2017-01-23 Otsuka Pharma Co Ltd CARBOSTYRIL DERIVATIVES AND Mood Stabilizers for the Treatment of Mood Disorders
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
EP1874282B1 (en) * 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
DK1909764T3 (da) * 2005-07-26 2014-12-15 Ucb Pharma Sa Farmaceutisk sammensætninger omfattende levetiracetam og fremgangsmåde til deres fremstilling
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US8211936B2 (en) * 2006-06-08 2012-07-03 Ucb Pharma, S.A. Co-crystals of pyrrolidinones
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
US20090176740A1 (en) * 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
CN101647789B (zh) * 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
EP2968237A4 (en) * 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044878A1 (en) * 2008-10-16 2010-04-22 The Johns Hopkins University Methods and compositions for improving cognitive function
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱杰等: "阿尔兹海默氏病及其药物治疗研究进展", 《广州化学》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115517682A (zh) * 2022-11-25 2022-12-27 四川大学华西医院 基于胃肠电信号的认知功能障碍预测系统及构建方法
CN115517682B (zh) * 2022-11-25 2023-01-31 四川大学华西医院 基于胃肠电信号的认知功能障碍预测系统及构建方法

Also Published As

Publication number Publication date
AU2021200325B2 (en) 2022-07-28
AU2022221492A1 (en) 2022-09-22
JP2016172772A (ja) 2016-09-29
BR112013020283A2 (pt) 2016-07-19
RU2018129580A (ru) 2019-03-20
AU2021200325A1 (en) 2021-03-18
AU2019268069A1 (en) 2019-12-12
EP2672822A4 (en) 2014-08-27
JP2018100305A (ja) 2018-06-28
US20120214859A1 (en) 2012-08-23
WO2012109491A1 (en) 2012-08-16
AU2016202670A1 (en) 2016-05-19
JP2014505108A (ja) 2014-02-27
EP3400934A1 (en) 2018-11-14
JP2023126654A (ja) 2023-09-07
JP2021175759A (ja) 2021-11-04
AU2012214303A1 (en) 2013-09-12
CA2826765C (en) 2021-04-06
CN103476255A (zh) 2013-12-25
CA2826765A1 (en) 2012-08-16
RU2665021C2 (ru) 2018-08-24
AU2018201303A1 (en) 2018-03-15
JP2020079318A (ja) 2020-05-28
JP2025109773A (ja) 2025-07-25
RU2018129580A3 (enExample) 2022-03-25
RU2013141155A (ru) 2015-03-20
US20230033195A1 (en) 2023-02-02
EP2672822A1 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
CN109662961A (zh) 用于改善认知功能的方法和组合物
US20210244709A1 (en) Methods and compositions for improving cognitive function
JP6440625B2 (ja) 精神分裂病を処置するための方法および組成物
CN109662964A (zh) 用于改善认知功能的方法和组合物
JP6808679B2 (ja) 認知機能を改善するための方法および組成物
US20160030391A1 (en) Methods and compositions for improving cognitive function
AU2018208662B2 (en) Methods and Compositions for Treating Schizophrenia
HK40003608A (en) Methods and compositions for improving cognitive function
RU2792010C2 (ru) Способы и композиции для улучшения когнитивных функций
HK1261244A1 (en) Levetiracetam for improving cognitive function
HK1192821A (en) Methods and compositions for improving cognitive function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003608

Country of ref document: HK